Life quality assessment of patients with stable coronary artery disease after myocardial revascularization

Cover Page

Cite item

Full Text

Abstract

The aim of this study is to assess the life quality of patients with stable coronary artery disease after angioplasty and stenting of coronary arteries at the post-hospital stage.

Materials and methods. Methods of the sociological analysis (questionnaire surveys) and methods of mathematical statistics (descriptive statistics, time series method, factor and variance analyses) were used at different stages of the prospective observational study. The research materials were as follows:1458 electronic patient records with a stable coronary heart disease (SCHD) after angioplasty and stenting of coronary arteries (ASCA); 620 questionnaires filled in by patients before the surgery, 1, 6, 12 months after discharge. The statistical analysis was performed using the IBM SPSS Statistics software.

Results. The results of a comprehensive survey make it possible for us to assert that during the studied period, stable good healths of cardiac surgery patients with ASCA were maintained. Within the framework of the EQ-5D-5L questionnaire, it was revealed that more than 50% of patients have no physiological problems. The results of the SAQ analysis demonstrate that 58% of the patients feel better, and more than 34% of the patients do not have shortness of breath 1 year after the surgery. A statistically significant improvement in their healths was established according to a visual analogue scale relatively to the annual observation mark (62.82 ±20.95), which corresponds to the high results assessment of the medical technology use. At the same time, 53% of the patients notify that the treatment results meet their own expectations.

Conclusion. The proposed calculation of the integrated index of patients’ treatment efficiency demonstrated by the patients with stable coronary heart disease after angioplasty and stenting of the coronary arteries is based on the results of the factor analysis. This calculation can be used to assess the efficiency of pharmacotherapy in the framework of a value-oriented approach to the treatment of a number of other pathologies.

About the authors

Igor A. Narkevich

Saint-Petersburg State Chemical Pharmaceutical University

Email: igor.narkevich@pharminnotech.com
ORCID iD: 0000-0002-5483-6626

Doctor of Pharmacy, Professor, the Head of the Department of Management and Economics of Pharmacy, Rector

Russian Federation, 14, Prof. Popov St., Saint-Petersburg, Russia, 197376

Oksana D. Nemyatykh

Saint-Petersburg State Chemical Pharmaceutical University

Email: oksana.nemyatyh@pharminnotech.com
ORCID iD: 0000-0001-5933-2120

Doctor of Sciences (Pharmacy), Associate Professor, Professor of the Department of Management and Economics of Pharmacy

Russian Federation, 14, Prof. Popov St., Saint-Petersburg, Russia, 197376

Ksenia A. Kovaleva

Saint-Petersburg State Chemical Pharmaceutical University

Author for correspondence.
Email: xenia.zagvozdina@pharminnotech.com
ORCID iD: 0000-0002-6647-2479

Assistant of the Department of Management and Economics of Pharmacy

Russian Federation, 14, Prof. Popov St., Saint-Petersburg, Russia, 197376

Lyudmila G. Ratova

Almazov National Medical Research Center

Email: Lratova@mail.ru
ORCID iD: 0000-0002-3109-034X

Candidate of Sciences (Medicine), Senior Researcher

Russian Federation, 2, Accuratov St., Saint-Petersburg, Russia, 197341

Irina O. Trushnikova

Saint-Petersburg State University of Economics

Email: itrushnikova@mail.ru
ORCID iD: 0000-0003-2640-7952

Candidate of Sciences (Ecomomics), Associate Professor of the Department of Marketing

Russian Federation, 21, Sadovaya St., Saint-Petersburg, Russia, 191023

Elena N. Parizhskaya

Almazov National Medical Research Center

Email: parizhskaya_en@almazovcentre.ru
ORCID iD: 0000-0003-3863-8547

Senior Researcher

Russian Federation, 2, Accuratov St., Saint-Petersburg, Russia, 197341

Alexandra O. Konradi

Almazov National Medical Research Center; Saint Petersburg National Research University of Information Technology, Mechanics and Optics (ITMO University)

Email: konradi_ao@almazovcentre.ru
ORCID iD: 0000-0001-8169-7812

Doctor of Sciences (Medicine), Professor, Corresponding Member, Russian Academy of Science, Deputy Director General for academic affairs, the Head of the Scientific Research Institute of Arterial Hypertension; Director of the Institute of Translational Medicine

Russian Federation, 2, Accuratov St., Saint-Petersburg, Russia, 197341; 49, Kronverksky Ave., Saint-Petersburg, Russia, 197101

References

  1. WHO (World Health Organization). 2020. The top 10 causes of death. Geneva: WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
  2. Kontsevaya AN, Drapkina OM, Balanova YuA, Imaeva AE, Suvorova EI, Khudyakov MB. Economic burden of cardiovascular diseases in the Russian Federation in 2016. Rational Pharmacotherapy in Cardiology. 2018;14(2):156–166. doi: 10.20996/1819-6446-2018-14-2-156-166.
  3. Paltsev MA, Belushkina NN, Chaban EA. 4P-Medicine as a new model of healthcare in the Russian Federation. Healthcare management: news. Views. Education. Bulletin of Higher School of Organization and Health Management. 2015. 2:48–54. Russian
  4. Osmanov EM, Manyakov RR, Osmanov RE, Zhabina UV, Konyaev DА, Agafonova YV, Peshkova АА. 4 “P” medicine as a basis of new system of public health. Tambov University Reports. Series: Natural and Technical Sciences 22(6):1680–1685. doi: 10.20310/1810-0198-2017-22-6-1680-1685. Russian
  5. Nemyatyh OD., Kovaleva K.A. Social’no-ekonomicheskie aspekty lekarstvennogo obespecheniya pacientov s serdechno-sosudistymi patologiyami v postoperacionnm periode / O.D. Nemyatyh, // Sbornik materialov IV Vserossijskoj nauchno-prakticheskoj konferencii s mezhdunarodnym uchastiem «Innovacii v zdorov’e nacii»: Sankt-Peterburg, 9-10 noyabrya 2016 g. – S. 445–447. Russian
  6. Kovaleva KA, Nemyatykh OD, Narkevich IA, Ratova LG, Parizhskaya EN, Konradi AO, Basakina II. analysis of the medicines’ range for therapy of patients with stable angina in the Russian Federation. Bashkortostan Medical Journal. 2019;14(5):43–47. Russian
  7. Kovaleva KA, Nemyatyh OD, Narkevich IA, Ratova LG, Parizhskaya EN, Konradi AO, Basakina II. Analysis of state purchases in the area of preferential provision of medicines for the patients with stable angina (evidence from Saint Petersburg) VestnikRoszdravnadzora. 2020;1:83–88. doi: 10.35576/2070-7940-2020-1-83-88. Russian
  8. Ratova LG, Parizhskaya EN, Kovaleva KA, Nedoshivin AO, Nemyatykh OD, Pulit VV, Konradi AO. An observational study to assess the outcomes of treatment of patients with stable angina after planned percutaneous coronary intervention: baseline patient characteristics. Russian Journal of Cardiology. 2018;(12):52–56. doi: 10.15829/1560-4071-2018-12-52-56. Russian
  9. Ratova LG, Parizhskaya EN, Kovaleva КA, Zvartau NE, Ionov МV, Semenov AP, Fedorenko АА., Nedoshivin АО, Nemyatykh ОD, Konradi АО. Evaluation of the outcomes of stable angina management after selective percutaneous coronary intervention (Pilot Results). Russian Journal of Cardiology. 2017;(12):8–13. doi: 10.15829/1560-4071-2017-12-8-13. Russian
  10. Chuchalin AG, Avdeev SN, Aysanov ZR, Belevskiy AS, Leshchenko IV, Meshcheryakova NN, Ovcharenko SI, Shmelev EI. Russian respiratory society. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonologiya. 2014;(3):15–54. doi: 10.18093/0869-0189-2014-0-3-15-54. Russian
  11. Amirdjanova VN, Erdes SF. Validation of general questionnaire EuroQol-5D (EQ-5D) Russian version. Rheumatology Science and Practice. 2007;45(3):69–76. doi: 10.14412/1995-4484-2007-691. Russian
  12. Syrkin AL, Pechorina EA, Drinitsina SI. Validation of methods for assessing the quality of life in patients with stable angina pectoris Clinical Medicine. 2001:79(11); 22–25. Russian
  13. Balackij EV. Faktory udovletvorennosti zhizn’yu: izmerenie i integral’nye pokazateli. Monitoring obshchestvennogo mneniya. 2005;4:42–52. Russian
  14. Sumin AN, Korok EV, Shcheglova AV, Barbarash OL. Comorbidities in patients with ischemic heart disease: gender differences. Rational Pharmacotherapy in Cardiology. 2017;13(5):622–629. doi: 10.20996/1819-6446-2017-13-5-622-629. Russian
  15. Mirzakhanova L.R. Efficacy of coronary stenting and basic pharmacotherapy in elderly and senile patients: the results of long-term prospective follow-up. Rational Pharmacotherapy in Cardiology. 2011;7(6):708–712. Russian
  16. Manzella D, Paolisso G. Cardiac autonomic activity and Type II diabetes mellitus. Clin Sci (Lond). 2005;108(2):93–9. doi: 10.1042/CS20040223.
  17. DeLuca AJ, Saulle LN, Aronow WS, Ravipati G, Weiss MB. Prevalence of silent myocardial ischemia in persons with diabetes mellitus or impaired glucose tolerance and association of hemoglobin A1c with prevalence of silent myocardial ischemia. Am J Cardiol. 2005;95(12):1472–4. doi: 10.1016/j.amjcard.2005.02.016.
  18. Lo KY, Chan CK. Characteristics and outcomes of patients with percutaneous coronary intervention for unprotected left main coronary artery disease: a Hong Kong experience. Hong Kong Med J. 2014 Jun;20(3):187–93. doi: 10.12809/hkmj134069.
  19. Hilliard AA, From AM, Lennon RJ, Singh M, Lerman A, Gersh BJ, Holmes DR Jr, Rihal CS, Prasad A. Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv. 2010 Feb;3(2):172–9. doi: 10.1016/j.jcin.2009.11.013.
  20. Averin EE, Apuhtin AF, Delaryu VV. Reabilitaciya pacientov kardiohirurgicheskogo profilya: kriticheskaya ocenka social’no-pravovoj bazy. YUrist – Pravoved”. 2010;4:42–44. Russian
  21. Clinical guidelines. Stable ischemic heart disease. (Cited: 28 Aug 2020). 2020:114. Available from: http://cr.rosminzdrav.ru/#!/schema/. Russian
  22. Karpova ES, Kotelnikova EV, Lyamina NP. Ischemic preconditioning and its cardioprotective effect in post-intervention cardiac rehabilitation programmes for patients with coronary heart disease. Russian Journal of Cardiology. 2012;(4):104–108. Russian
  23. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394.
  24. Martynova VV, Andreev DA, Doletskiĭ AA, Abugov SA, Saakian IuM. Safety and efficacy of early physical rehabilitation after planned percutaneous coronary interventions. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2013;6(5):11–16.
  25. Kuznetsov VA, Samoylova EP, Bessonov IS, Gultyaeva EP, Zyryanov IP, Berdinskikh SG, Gorbatenko EA, Kolunin GV. Long term results of percutaneous coronary interventions comparing with conservative management in treatment of stable ischemic heart disease patients under real circumstances. Russian Journal of Cardiology. 2016;(2):7–11. doi: 10.15829/1560-4071-2016-2-7-11. Russian
  26. Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben-Yehuda O, van Es GA, Taggart DP, Morice MC, Lembo NJ, Brown WM 3rd, Banning A, Simonton CA, Kappetein AP, Sabik JF, Serruys PW, Stone GW, Cohen DJ; EXCEL Investigators. Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial. J Am Coll Cardiol. 2017;70(25):3113–3122. doi: 10.1016/j.jacc.2017.10.036.
  27. Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben-Yehuda O, van Es GA, Taggart DP, Morice MC, Lembo NJ, Brown WM 3rd, Banning A, Simonton CA, Kappetein AP, Sabik JF, Serruys PW, Stone GW, Cohen DJ; EXCEL Investigators. Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial. J Am Coll Cardiol. 2017;70(25):3113–22. doi: 10.1016/j.jacc.2017.10.036.
  28. Jensen LO, Thayssen P, Maeng M, Christiansen EH, Ravkilde J, Hansen KN, Kaltoft A, Tilsted HH, Madsen M, Lassen JF; Scandinavian Organization for Randomized Trials With Clinical Outcome SORT OUT IV Investigators. Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial. JACC Cardiovasc Interv. 2014 Aug;7(8):840–8. doi: 10.1016/j.jcin.2014.02.014.
  29. Contracting for Outcomes A Value-Based Approach. 2014. [Cited: 10 Aug 2020]. Available from: http://outcomesbasedhealthcare.com/Contracting_for_Outcomes.pdf. Subscription required.
  30. Outcomes based approaches to healthcare. Outcomes based approaches to healthcare Ltd. 2014. [Cited: 10 Aug 2020]. Available from: http://outcomesbasedhealthcare.com/OBH_Outcomes_Myths_2014.pdf. Subscription required.
  31. Latkovic T. The Trillion Dollar Prize. Using outcomes-based payment to address the US healthcare financing crisis. McKinsey and Company. 2013. [Cited: 10 Aug 2020].: 40. Available from: http://healthcare.mckinsey.com/sites/default/files/the-trillion-dollar-prize.pdf. Subscription required.
  32. Bae JM. Value-based medicine: concepts and application. Epidemiol Health. 2015 Mar 4;37:e2015014. doi: 10.4178/epih/e2015014.
  33. Kelly MP, Heath I, Howick J, Greenhalgh T. The importance of values in evidence-based medicine. BMC Med Ethics. 2015 Oct 12;16(1):69. doi: 10.1186/s12910-015-0063-3.
  34. Shlyakhto EV, Vasilievich YuI. Outcome-based healthcare. Translational Medicine. 2017;4(1):6–10. Russian
  35. Shlyahto EV, Konradi AO. Medicina, osnovannaya na cennosti, –novaya paradigma v zdravoohranenii. Remedium Privolzh’e. 2018;3(163):4–8.

Copyright (c) 2020 Narkevich I.A., Nemyatykh O.D., Kovaleva K.A., Ratova L.G., Trushnikova I.O., Parizhskaya E.N., Konradi A.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies